iifl-logo-icon 1

Ganga Pharmaceuticals Ltd Share Price

24.67
(0.00%)
Jun 24, 2024|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Equities

Futures

Option

  • Open24.67
  • Day's High24.67
  • 52 Wk High28.49
  • Prev. Close24.67
  • Day's Low24.67
  • 52 Wk Low7.5
  • Turnover (lac)1.97
  • P/E246.7
  • Face Value10
  • Book Value14.59
  • EPS0.1
  • Mkt. Cap (Cr.)11.93
  • Div. Yield0
No Records Found

Ganga Pharmaceuticals Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

24.67

Prev. Close

24.67

Turnover(Lac.)

1.97

Day's High

24.67

Day's Low

24.67

52 Week's High

28.49

52 Week's Low

7.5

Book Value

14.59

Face Value

10

Mkt Cap (₹ Cr.)

11.93

P/E

246.7

EPS

0.1

Divi. Yield

0

Ganga Pharmaceuticals Ltd Corporate Action

6 May 2024

12:00 AM

Board Meeting

Agenda : Audited Result

arrow

4 Dec 2023

12:00 AM

EGM

arrow

7 Aug 2023

12:00 AM

BookCloser

arrow

7 Aug 2023

12:00 AM

AGM

Announcement Date: 07 Aug, 2023

arrow

Ganga Pharmaceuticals Ltd NEWS AND UPDATE

No data found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Ganga Pharmaceuticals Ltd SHAREHOLDING SNAPSHOT

22 Jul, 2024|02:31 PM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 56.02%

Foreign: 0.00%

Indian: 56.02%

Non-Promoter- 43.97%

Institutions: 0.00%

Non-Institutions: 43.97%

Custodian: 0.00%

Share Price

Ganga Pharmaceuticals Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Loading...
Y/e 31 Mar( In .Cr)Mar-2023Mar-2022Mar-2021Mar-2020

Equity Capital

4.06

4.06

4.06

4.06

Preference Capital

0

0

0

0

Reserves

1.39

1.35

1.31

1.29

Net Worth

5.45

5.41

5.37

5.35

Minority Interest

View Balance Sheet
Loading...
Y/e 31 Mar( In .Cr)Mar-2021Mar-2020Mar-2018Mar-2017

Revenue

2.37

3.07

3.05

3.01

yoy growth (%)

-22.88

0.85

1.4

14.51

Raw materials

-1.23

-1.27

-1.15

-1.06

As % of sales

52.08

41.48

37.97

35.31

Employee costs

-0.42

-0.43

-0.43

-0.33

View Profit & Loss
Loading...
Y/e 31 Mar( In .Cr)Mar-2021Mar-2020Mar-2018Mar-2017

Profit before tax

0.03

0.25

0.12

0.1

Depreciation

-0.05

-0.05

-0.05

-0.04

Tax paid

-0.01

-0.06

-0.03

-0.03

Working capital

0.35

0.27

-0.22

-0.59

Other operating items

View Cash Flow
Loading...
Y/e 31 MarMar-2021Mar-2020Mar-2018Mar-2017

Growth matrix (%)

Revenue growth

-22.88

0.85

1.4

14.51

Op profit growth

-91.96

21.96

2.83

1.79

EBIT growth

-53.42

23.04

-4.42

6.8

Net profit growth

-89.21

100.78

26.76

52.37

View Ratios
Particulars (Rupees in Crores.)Mar-2021Mar-2020

Gross Sales

2.37

3.08

Excise Duty

0

0

Net Sales

2.37

3.08

Other Operating Income

0

0

Other Income

0.25

0.17

Ganga Pharmaceuticals Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceuticals Industries Ltd

SUNPHARMA

1,568.45

123.313,76,323.69867.60.865,536.9998.75

Divis Laboratories Ltd

DIVISLAB

4,520.1

76.171,19,994.455310.662,259507.93

Cipla Ltd

CIPLA

1,485.15

32.291,19,928.541,038.40.573,444.92346.41

Zydus Lifesciences Ltd

ZYDUSLIFE

1,144.6

33.511,15,173.541,405.20.263,172.6156.19

Dr Reddys Laboratories Ltd

DRREDDY

6,639.05

25.851,10,759.071,034.80.65,081.81,458.96

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Ganga Pharmaceuticals Ltd

Management

Register Office

Registrar Office

Chairman & Non Executive Dir.

SANJAY VYANKATESH KULKARNI

Managing Director & CEO

BHARAT BRIJMOHAN SHARMA

Whole-time Director

SRIJNA SHARMA

Independent Director

SACHIN CHANDRAKANT CHAVAN

Independent Director

CHETAN BHIKHUBHAI PATEL

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Summary

Ganga Pharmaceuticals Ltd was incorporated as a Public Limited Company in Aug.94 and promoted by Brij Mohan Sharma. he Company is engaged in the business of manufacturing & trading in Pharmaceuticals & allied products (Ayurveda).In Apr.95, the company took over Ganga pharmaceuticals, a proprietory concern (owned by the same promoter), which was manufacturing and marketing ayurvedic products since the last two decades. The company which manufactures ayurvedic medicines, started commercial production in Apr.95. In Jul.96, it came out with a public issue to part-finance the expansion programme involving setting up of a new manufacturing unit for the manufacture of ayurvedic medicines at Murbad, Maharashtra.The company which commenced exports in Jan.96, has marketing arrangements with parties located in Saudi Arabia, Dubai, Italy, Romania and Russia to market its products in their respective regions.
Read More

Company FAQs

What is the Ganga Pharmaceuticals Ltd share price today?

Down Arrow

The Ganga Pharmaceuticals Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is Rs.₹24.67 today.

What is the Market Cap of Ganga Pharmaceuticals Ltd?

Down Arrow

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Ganga Pharmaceuticals Ltd is ₹11.93 Cr. as of 24 Jun ‘24

What is the PE and PB ratio of Ganga Pharmaceuticals Ltd?

Down Arrow

The PE and PB ratios of Ganga Pharmaceuticals Ltd is 246.7 and 1.69 as of 24 Jun ‘24

What is the 52 Week High and Low of Ganga Pharmaceuticals Ltd?

Down Arrow

The 52-week high/low is the highest and lowest price at which a Ganga Pharmaceuticals Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Ganga Pharmaceuticals Ltd is ₹7.5 and ₹28.49 as of 24 Jun ‘24

What is the CAGR of Ganga Pharmaceuticals Ltd?

Down Arrow

Ganga Pharmaceuticals Ltd's CAGR for 5 Years at 32.68%, 3 Years at 60.20%, 1 Year at 196.51%, 6 Month at -9.10%, 3 Month at 4.98% and 1 Month at N/I%.

What is the shareholding pattern of Ganga Pharmaceuticals Ltd?

Down Arrow

The shareholding pattern of Ganga Pharmaceuticals Ltd is as follows:
Promoters - 56.02 %
Institutions - 0.00 %
Public - 43.98 %

Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.